NCT00567905

Brief Summary

The purpose of this study is to examine the effect of green tea extract (GTE) on type 2 diabetes and to explore the relationship between GTE and related hormone peptides.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at below P25 for phase_2 type-2-diabetes

Timeline
Completed

Started Sep 2007

Shorter than P25 for phase_2 type-2-diabetes

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2007

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

December 4, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 5, 2007

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2008

Completed
Last Updated

January 13, 2009

Status Verified

January 1, 2009

Enrollment Period

11 months

First QC Date

December 4, 2007

Last Update Submit

January 12, 2009

Conditions

Keywords

Type 2 DiabetesGreen tea extractoverweight

Outcome Measures

Primary Outcomes (1)

  • Homeostasis model assessment for insulin resistance (HOMA-IR) was used as the major outcome measurement.

    16 weeks

Secondary Outcomes (1)

  • HbA1C, blood sugar, creatinine, aminotransferases aspartate, aminotransferases alanine, uric acid, and plasma lipoproteins (triglyceride, cholesterol, cholesterol-HDL (HDL) and cholesterol-LDL (LDL)) cholesterol; BMI,WC---.

    16 weeks

Study Arms (2)

A

EXPERIMENTAL

Green tea extract

Dietary Supplement: Green tea extract

B

PLACEBO COMPARATOR
Dietary Supplement: Green tea extract

Interventions

Green tea extractDIETARY_SUPPLEMENT

main content is epigallocatechin gallate (EGCG, 58%)

Also known as: A:GTE (500 mg) tid/day, B:Placebo (cellulose, 500 mg) tid/day
AB

Eligibility Criteria

Age20 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetes
  • Body mass index \>25 kg/mm
  • Aged between 20 and 65 years
  • Being Chinese

You may not qualify if:

  • Aminotransferases aspartate or aminotransferases alanine \> 80 IU/L, serum creatinine \> 2.0 mg/dl,
  • Prolating or pregnant women, and patients with heart failure, acute myocardiac infarct, stroke and heavy injuries, and
  • Any other conditions not suitable for trial as evaluated by the physician.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Branch of Chinese Medicine, Taipei City Hospital

Taipei, 886, Taiwan

Location

Branch of Chinese Medicine

Taipei, 886, Taiwan

Location

Related Publications (2)

  • Kao YH, Chang HH, Lee MJ, Chen CL. Tea, obesity, and diabetes. Mol Nutr Food Res. 2006 Feb;50(2):188-210. doi: 10.1002/mnfr.200500109.

    PMID: 16416476BACKGROUND
  • Hsu CH, Liao YL, Lin SC, Tsai TH, Huang CJ, Chou P. Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. Altern Med Rev. 2011 Jun;16(2):157-63.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Overweight

Interventions

TeaCellulose

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Plant PreparationsBiological ProductsComplex MixturesBeveragesDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesGlucansBiopolymersPolymersMacromolecular SubstancesPolysaccharidesCarbohydratesBiomedical and Dental MaterialsManufactured MaterialsTechnology, Industry, and Agriculture

Study Officials

  • Chung-Hua Hsu, MD; PhD

    Branch of Chinese Medicine, Taipei City Hospital

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 4, 2007

First Posted

December 5, 2007

Study Start

September 1, 2007

Primary Completion

August 1, 2008

Study Completion

August 1, 2008

Last Updated

January 13, 2009

Record last verified: 2009-01

Locations